Bilateral Pheochromocytoma Associated with Paraganglioma and Papillary Thyroid Carcinoma: Report of an Unusual Case

JEONG HOON YANG, SUNG JIN BAE, SANGHUI PARK*, HYUN-KYUNG PARK**, HYE SEUNG JUNG, JAE HOON CHUNG, YONG-KI MIN, MYUNG-SHIK LEE, KWANG-WON KIM AND MOON-KYU LEE

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea
*Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea
**Department of Laboratory Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea

Abstract. A 42-year old woman presented with headache, palpitation and facial flushing. Ultrasonograms and computed tomograms revealed tumors in both of the adrenal glands, anterior aspect of the inferior vena cava, and the right lobe of the thyroid gland. Fine needle aspiration biopsy of the thyroid nodule revealed papillary thyroid carcinoma. Serum calcitonin, CEA, intact PTH and calcium levels were within normal limits. Markedly elevated levels of urinary normetanephrine and vanillylmandelic acid, and the result of 131I-metaiodobenzylguanidine (131I-MIBG) scintigraphy indicated that both adrenal masses were pheochromocytoma. Bilateral adrenalectomy, paracaval mass removal and total thyroidectomy together with central lymph node dissection were performed. The final pathological diagnosis was bilateral adrenal pheochromocytoma, paraganglioma, papillary thyroid carcinoma and either parathyroid adenoma or hyperplasia. Analysis of the RET proto-oncogene mutation, von Hippel Lindau mutation, succinate dehydrogenase subunit B mutation, and succinate dehydrogenase subunit D mutation yielded negative results. The relationship of these lesions could not be determined. This is the first report of a combination of bilateral pheochromocytoma, abdominal paraganglioma, papillary thyroid carcinoma and either parathyroid adenoma or hyperplasia without hyperparathyroidism.

Key words: Pheochromocytoma, Paraganglioma, Papillary thyroid carcinoma

(Endocrine Journal 54: 227–231, 2007)

PHEOCHROMOCYTOMA and abdominal paragangliomas are catecholamine-producing tumors that arise from paraganglia cells derived from the neural crest. Tumors that arise from cells within the adrenal medulla are defined as pheochromocytoma, whereas tumors arising from the paraganglia located outside the adrenals are called paragangliomas or extra-adrenal pheochromocytomas [1]. While pheochromocytomas occur most commonly as sporadic tumors, approximately 25% of these tumors are inherited as part of a distinct syndrome such as von Hippel Lindau syndrome (VHL), multiple endocrine neoplasia type 2 (MEN 2), neurofibromatosis type 1 and paraganglioma syndrome [2]. In MEN 2, there is an association between medullary thyroid carcinoma and pheochromocytoma. However, papillary thyroid carcinoma is rarely associated with pheochromocytoma, and the relationship between pheochromocytoma and papillary thyroid carcinoma remains unclear [3–5].

We present here an unusual case of a patient who had bilateral pheochromocytoma, abdominal paraganglioma, papillary thyroid carcinoma and either parathyroid adenoma or hyperplasia without hyperparathyroidism. The relationship of these lesions is discussed.

Case Report

A 42-year old woman presented with headache, palpitation, and facial flushing which started seven months prior. She was diagnosed with hypertension one year earlier. The blood pressure was 148/77
mmHg and the pulse rate was 97 beats per minute. The physical examination revealed no abnormal findings. There was no specific family history.

Urinary metanephrine, normetanephrine and vanillylmandelic acid (VMA) levels from a 24 hour urine sample were 234.68 µg/day (45 to 290 µg/day), 5435.25 µg/day (82–500 µg/day) and 9.5 mg/day (normal <6.8 mg/day), respectively. Serum calcitonin and CEA levels were within normal limits. Serum intact PTH and calcium levels were also within normal limits (Table 1). Abdominal computed tomography (CT) showed heterogeneously enhanced bilateral adrenal masses (right side size: 4.6 cm × 2.8 cm; left side size: 2.5 cm × 2.1 cm) and another 1.6 cm × 1 cm sized enhancing lesion at the anterior aspect of the inferior vena cava (Fig. 1). ¹³¹I-MIBG scintigraphy demonstrated an increased uptake over the bilateral adrenal masses (Fig. 2). Ultrasonography of the thyroid gland showed an approximately 0.6 cm-sized, irregularly marginated calcified nodule in the right thyroid gland, and this was diagnosed as a papillary thyroid carcinoma by fine needle aspiration and cytology. The patient underwent bilateral adrenalectomy, paracaval mass removal and total thyroidectomy together with central lymph node dissection. Four parathyroids were carefully preserved, but one parathyroid (4 mm × 3 mm × 3 mm) was incidental and was removed with thyroid. The final pathological diagnosis was bilateral adrenal pheochromocytoma (Fig. 3A), paraganglioma (Fig. 3B), papillary thyroid carcinoma (stage 1, T1N1M0) (Fig. 3C) and either parathyroid adenoma or hyperplasia (Fig. 3D). Immunohistochemically, chromogranin A staining as specific marker was positive and Ki67 staining as a marker of recurrence or metastasis was not significantly immunoreactive (Fig. 3E, 3F). Postoperatively, the hypertension and related symptoms were resolved and the level of urinary catecholamine metabolites recovered to their normal values. Two hundred microliters of blood were used for genomic DNA extraction using the Wizard Genomic DNA Purification Kit following the manufacturer’s instructions (Promega, Madison, WI). Genomic DNA was also extracted from papillary thyroid carcinoma using the High Pure PCR Table 1. Preoperative data on endocrine factors

<table>
<thead>
<tr>
<th>Laboratory data</th>
<th>Values</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Free T4</td>
<td>1.15 ng/dl</td>
<td>0.64–1.72</td>
</tr>
<tr>
<td>TSH</td>
<td>1.93 uIU/ml</td>
<td>0.3–6.5</td>
</tr>
<tr>
<td>CEA</td>
<td>0.82 ng/ml</td>
<td>0–5</td>
</tr>
<tr>
<td>Calcitonin</td>
<td>3 pg/ml</td>
<td>0–13</td>
</tr>
<tr>
<td>Calcium</td>
<td>8.5 mg/dl</td>
<td>8.4–10.2</td>
</tr>
<tr>
<td>Intact PTH</td>
<td>38.8 pg/ml</td>
<td>10–65</td>
</tr>
<tr>
<td>Urine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VMA</td>
<td>9.5 mg/day</td>
<td>&lt;6.8</td>
</tr>
<tr>
<td>Metanephrine</td>
<td>234.68 µg/day</td>
<td>45–290</td>
</tr>
<tr>
<td>Normetanephrine</td>
<td>5435.25 µg/day</td>
<td>82–500</td>
</tr>
</tbody>
</table>

Abbreviations: TSH; thyroid stimulating hormone; CEA; carcinoembryonic antigen; PTH; parathyroid hormone; VMA; vanillylmandelic acid.
Bilateral Pheochromocytoma Associated with Papillary Thyroid Carcinoma

The coding exons and their flanking introns of the RET (exon 10, 11, 13, 14, 15 and 16), von Hippel Lindau (VHL), succinate dehydrogenase subunit B (SDHB), and succinate dehydrogenase subunit D (SDHD) genes were amplified using primers designed by the authors (available on request). Direct sequencing was performed with the BigDye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems, Foster City, CA) on the ABI 3100 Genetic Analyzer (Applied Biosystems). Analysis of the RET, VHL, SDHB, and SDHD genes yielded no mutation. Furthermore, we also analyzed somatic mutation of the RET, but no mutation was detected.

Discussion

We have described a case of bilateral pheochromocytoma associated with abdominal paraganglioma, papillary thyroid carcinoma and either parathyroid adenoma or hyperplasia. Generally, patients with bilateral pheochromocytoma are more likely to have a genetic basis for their disease. During the past ten years, it has been recognized that pheochromocytomas are tumors commonly found in patients with VHL, MEN 2 and neurofibromatosis type 1, occurring as a result of germline mutations in VHL, RET or NF1, respectively [6]. The frequency of germline mutations in these genes was much higher than previously estimated. More recently nuclear genes encoding two mitochondrial complex II subunit proteins, SDHD and SDHB, have been associated with the development of familial pheochromocytomas and paragangliomas [7, 8]. Head and neck paraganglioma were statistically more prevalent among SDHD carriers compared with those with SDHB mutations, although intra-abdominal tumors were more prevalent among SDHB mutation carriers [9]. For SDHB mutation carriers, a high rate of distant metastases has been reported, and consistent with the apparently aggressive nature of SDHB dysfunction, some carriers of the mutation were also found to have extraparaganglial malignancies (e.g., renal cell carcinoma and papillary thyroid carcinoma) [9]. But whether these extraparaganglial malignancies are also components of SDHB related disease awaits further confirmation.

The association of thyroid carcinoma in patients with pheochromocytoma is 14 times greater than in the general population. The increased incidence might be due to the fluctuating thyrotropin secretion caused by circulating catecholamines [10–12]. The association of medullary thyroid carcinoma with pheochromocytoma is well known in Sipple’s syndrome (MEN 2A) [3, 10–13]. However, the association between papil-
lary thyroid carcinoma and adrenal or extraadrenal pheochromocytoma is rare [3, 5, 10]. In 1983, Sato et al. reviewed 526 Japanese cases of pheochromocytoma and reported that three of them were associated with papillary thyroid carcinoma [14]. Pheochromocytomas are capable of producing and secreting a number of peptides such as insulin-like growth factor II [15], hypothalamic-like and pituitary-like hormones [16]. These biological substances might cause the development and growth of papillary thyroid carcinoma [10].

Although the pathological association of thyroid and parathyroid disease is common, the association of both parathyroid adenoma and thyroid cancer is rare [17]. Steiner et al. suggested that association of parathyroid tumors and papillary thyroid carcinoma might occur as in MEN 3 [18]. Ellenberg et al. reported that seven of a series of 93 cases of parathyroid adenoma were associated with adenocarcinoma of the thyroid gland. They speculated that hypercalcemia caused by parathyroid adenoma acted as a goitrogen capable of stimulating the thyroid to develop thyroid carcinoma [19].

Our patient had bilateral pheochromocytoma, abdominal paraganglioma, papillary thyroid carcinoma and either parathyroid adenoma or hyperplasia. But the levels of serum calcium and intact PTH were within normal limits and there was no evidence of medullary thyroid carcinoma, RET proto-oncogene germline or somatic mutations, and VHL germline mutations. The clinical features of the patient were not compatible with the diagnosis of VHL syndrome or neurofibromatosis type 1 nor was there evidence of SDHB, SDHD germline mutations. Therefore, it is likely that each tumor in this case developed sporadically. This is the first reported case of a combination of bilateral pheochromocytoma, paraganglioma, papillary thyroid carcinoma and either parathyroid adenoma or hyperplasia without hyperparathyroidism. The relationship of these lesions remains unclear in this patient. However, our findings might provide a clue for the existence of an evolving syndrome of multiple endocrine neoplasia.

References


